Iproniazid
From Wikipedia, the free encyclopedia
|
Iproniazid
|
|
| Systematic (IUPAC) name | |
| N'-isopropylisonicotinohydrazide | |
| Identifiers | |
| CAS number | |
| ATC code | N06 |
| PubChem | |
| Chemical data | |
| Formula | C9H13N3O |
| Mol. mass | 179.219 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes | ? |
Iproniazid (Marsilid, Iprozid, Ipronid, Rivivol, Propilniazida) is a hydrazine drug that was previously used as an antidepressant.[1] It is an irreversible and nonselective monoamine oxidase inhibitor (MAOI).[2] It has been widely discontinued.
[edit] History
Iproniazid was the first antidepressant ever marketed. It was originally intended for the treatment of tuberculosis.[1] In 1952, its antidepressant properties were discovered when researchers noted that the patients given iproniazid became "inappropriately happy".[1] It was subsequently developed as an antidepressant and was approved for use in 1958.[1] It was later withdrawn in 1961 due to the unacceptable incidence of hepatitis and was replaced by less hepatotoxic drugs like isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).[1]
Iproniazid was developed using the same hydrazine that was used to power German V-2 rockets.[3]
[edit] References
- ^ a b c d e Robert A. Maxwell, Shohreh B. Eckhardt (1990). Drug discovery. Humana Press. p. 455. ISBN 0896031802, 9780896031807.
- ^ Fagervall I, Ross SB (April 1986). "Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors". Biochemical pharmacology 35 (8): 1381–7. PMID 2870717. http://linkinghub.elsevier.com/retrieve/pii/0006-2952(86)90285-6.
- ^ [1]López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563-86.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

